The phase 3 trial was conducted by licensee, Grand Pharma in Chinese cataract surgery patients. Formosa Pharmaceuticals has ...
FELIQS plans to conduct a Phase 1b/2 study of FLQ-101 (tROPhy-1 study) both in the US and Japan in the first quarter of 2025.
The Valeda Light Delivery System is for the treatment of patients with dry age-related macular degeneration (AMD).
The investigators conducted a randomized controlled trial of 60 patients who underwent monitored anesthesia care sedation for ...
Robert T. Chang, MD, from Stanford University discusses how large language models are transforming ophthalmology by enhancing ...
In an interview with David Hutton of Ophthalmology Times, Ash Abbey, MD, discusses the Phase 3 LUGANO trial for EYP-1901 in treating wet age-related macular degeneration. Abbey discusses the trial’s ...
A group of German researchers has discovered how tiny eye movements and the density of photoreceptors assist in visual acuity ...
Researchers receive $6.4 million grant from NEI to seek new treatment for blindness-causing diseases
Rensselaer researchers receive $6.4 million grant from NEI to seek new treatment for blindness-causing diseases.
The investigators explained that AMN, a rare disease, is characterized by dark reddish, wedge-shaped macular lesions. 2 Impairment of the retinal deep capillary plexus also occurs and suggests ...
Dropless cataract surgery eliminates postoperative eye drops, enhancing patient adherence and reducing complications like ...
Jibran Sharieff, MD, and Brandon Kingrey, MD, discuss their innovative smartphone-based device for affordable retinal imaging ...
Chronic therapy is essential for PCV patients, even after resolution of pigment epithelial detachment, to prevent recurrence.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback